Biotech

Career and Jobs

Biotech Career and Jobs Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 28.10.2022.

#BioSpace
#Biotech
#LifeSciences
#innovation
#LifeScience
#EmpoweredByPurpose
#NowHiring
#Biopharma
#QuietQuitting
#pharma

@Biotechnology shared
On Oct 25, 2022
The 5 Most Affordable Cities for Biopharma Jobs in the US https://t.co/L5PpWMkBit https://t.co/jZLBhGppkg
Open
The 5 Most Affordable Cities for Biopharma Jobs in the US

The 5 Most Affordable Cities for Biopharma Jobs in the US

If you want to maximize your career earnings, it pays to consider which cities are the most affordable. Here are the top five most affordable cities for biopharma in the U.S.

@BioRadCareers shared
On Oct 26, 2022
Now hiring engineers. Sign up now for an interview during our virtual career fair on Thursday, October 27th. https://t.co/qP5KNmDFFv #NowHiring #EmpoweredByPurpose #Biotech https://t.co/w2dpkjTUHb
Open
VIRTUAL RECRUITING EVENTS

VIRTUAL RECRUITING EVENTS

We are a global team of innovators, builders, and leaders who create a broad array of clinical diagnostics and life science research products for thousands of customers across the globe. ...

@biospace shared
On Oct 27, 2022
By now, many have heard of the workplace phenomenon dubbed quiet quitting. The practice has made its mark in every industry, and life sciences is no exception. #QuietQuitting #LifeSciences #BioSpace https://t.co/DaEELJPgiK https://t.co/oxnSeHVyaT
Open
Quiet Quitting: Signs, Effects and Prevalence in the Biopharma Industry

Quiet Quitting: Signs, Effects and Prevalence in the Biopharma Industry

BioSpace's Recruitment Market Q3 Update shows that both employers and employees in life sciences have noticed quiet quitting in action. Read on to find out the signs, effects and prevalence ...

@BioWorld shared
On Oct 26, 2022
Biopharma survival via restructurings and workforce reductions (free w/registration) https://t.co/19N4CXsYlJ #biotech #pharma
Open
Biopharma survival via restructurings and workforce reductions

Biopharma survival via restructurings and workforce reductions

More than 15,700 employees at 101 biopharma companies have lost their jobs in 2022 as industry leaders struggle to stay afloat in an uncertain and challenging economic environment. ...

@MALifeSciences shared
On Oct 28, 2022
RT @MansfieldBioinc: Grateful to @MALifeSciences for making last week's Grand Opening possible. Together we grow Boston-Providence #lifesciences #innovation corridor. See the press-release, photos, and a video replay below. https://t.co/67mjObsWzK https://t.co/sz8fZgfmGl https://t.co/NTgUWPfk7I
Open
Mansfield Bio-Incubator Unveils Expanded Lab Campus

Mansfield Bio-Incubator Unveils Expanded Lab Campus

With 26,000 total square feet of lab space, the expansion cements the non-profit incubator as one of the largest collaborative life sciences spaces in Massachusetts’s booming biotech ...

@pharminews shared
On Oct 25, 2022
Becker Microbial Products Acquired by Founders of Proventus Bioscience https://t.co/fgiDomMgYT #PharmaNews #ClinicalResearchNews #BiotechNews #LifeSciencesNews #MedicalNews #HealthcareNews #PharmiwebNews https://t.co/v1P38He2Dx
Open
Becker Microbial Products Acquired by Founders of Proventus Bioscience

Becker Microbial Products Acquired by Founders of Proventus Bioscience

Innovative biotech company founders acquire another industry powerhouse. PARKLAND, Fla. ...

@Alnylam shared
On Oct 27, 2022
This morning, we reported Q3 2022 financial results and highlights of recent period activity. We will host a LIVE webcast TODAY at 8:30 AM EDT to discuss and a replay will be available following. Access the webcast and replay here: https://t.co/Pz1dtBf1wv $ALNY #RNAi #siRNA
Open
@JohnCendpts shared
On Oct 24, 2022
https://t.co/rzkmAcVNdR
Open
CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock

CD28 kills again? Mitch Gold’s plan to make cell therapy 2.0 history crashes after another patient dies of cardiogenic shock

Mitch Gold’s plans to push the envelope on cell therapy 2.0 has crashed into a fresh safety issue — and this time his biotech is ready to call it quits on the lead in-house effort. Seven ...